Last reviewed · How we verify
Lactobacillus reuteri DSM 17938
Lactobacillus reuteri DSM 17938, marketed by Eskisehir Osmangazi University, holds a niche position in the probiotics market. The key composition patent, set to expire in 2028, provides a significant barrier to entry for competitors. However, the lack of revenue data and primary trial results poses a risk in assessing the drug's commercial viability and therapeutic efficacy.
At a glance
| Generic name | Lactobacillus reuteri DSM 17938 |
|---|---|
| Also known as | BioGaia |
| Sponsor | Eskisehir Osmangazi University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuvant/Conversion Immunotherapy in Patients With Primary Resectable Liver Cancer (NA)
- The Effects of Probiotic Supplementation on State and Trait Stress, Anxiety, and Depression Symptoms in Stressed Adults (NA)
- Role of Probiotic Use in Outcomes of Premature Birth (NA)
- Prevalence of FGIDs and Probiotics Study (NA)
- Lactobacillus Reuteri Strain Combination in Children Treated With PPI (NA)
- Prophylactic Probiotics to Extremely Low Birth Weight Prematures (PHASE2)
- Effects of Probiotic Oral Intake on Plasma Chlordecone (Kepone) Concentrations in Individuals Environmentally Exposed to Pesticide in Martinique. (NA)
- Lactobacillus Reuteri Strains for Gingivitis Reduction (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus reuteri DSM 17938 CI brief — competitive landscape report
- Lactobacillus reuteri DSM 17938 updates RSS · CI watch RSS
- Eskisehir Osmangazi University portfolio CI